<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Magnesium chloride: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Magnesium chloride: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Magnesium chloride: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11214" href="/d/html/11214.html" rel="external">see "Magnesium chloride: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12976" href="/d/html/12976.html" rel="external">see "Magnesium chloride: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F190783"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nu-Mag [OTC] [DSC];</li>
<li>Slow Magnesium/Calcium [OTC];</li>
<li>Slow-Mag [OTC];</li>
<li>SlowMag Mg Muscle/Heart [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F190792"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Electrolyte Supplement, Oral;</li>
<li>
                        Electrolyte Supplement, Parenteral;</li>
<li>
                        Magnesium Salt</li></ul></div>
<div class="block doa drugH1Div" id="F190784"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Serum magnesium is poor reflection of repletional status as the majority of magnesium is intracellular; serum levels may be transiently normal for a few hours after a dose is given; therefore, aim for consistently high normal serum levels in patients with normal renal function for most efficient repletion.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8777829e-571e-43c9-b8bb-6fd78d640f11">Hypomagnesemia, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypomagnesemia, prevention (parenteral nutrition supplementation) (ASPEN [Mirtallo 2004]):</b> IV (elemental magnesium): 8 to 20 mEq/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="81863c66-ac4f-45ff-b638-ded564c6efe2">Dietary supplement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary supplement:</b> Oral: 2 tablets once daily.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991121"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">According to the manufacturer's labeling, use is contraindicated in renal impairment.</p></div>
<div class="block doha drugH1Div" id="F50988439"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F190785"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F190789"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12976" href="/d/html/12976.html" rel="external">see "Magnesium chloride: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing presented in mg and mEq; verify dosing units; 1,000 mg of magnesium chloride = 119.7 mg <b>elemental</b> magnesium = 9.85 mEq <b>elemental</b> magnesium = 4.93 mmol <b>elemental</b> magnesium.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="17f3d8ea-e8de-4fac-bdfb-5dade41876cd">Hypomagnesemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypomagnesemia:</b> Limited data available: <b>Note:</b> Serum magnesium is a poor reflection of repletion status, as the majority of magnesium is intracellular; serum concentrations may be transiently normal for a few hours after a dose is given; therefore, aim for consistently high normal serum concentrations in patients with normal renal function for most efficient repletion.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Infants, Children, and Adolescents: Dose expressed as <b>elemental magnesium</b>: IV: 2.5 to 5 mg/kg/dose every 6 hours for 2 to 3 doses; dosing based on experience with magnesium sulfate salt, which is preferred (Greenbaum 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: <b>Note:</b> Achieving optimal magnesium levels using oral therapy may be difficult due to the propensity for magnesium to cause diarrhea; IV replacement may be more appropriate, particularly in situations of severe deficit.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: Dose expressed as <b>elemental magnesium</b>: Oral: 10 to 20 mg/kg/dose up to 4 times daily (Gal 2007).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49f9f738-6af6-4f95-9a2d-632309e0274b">Parenteral nutrition, maintenance magnesium requirement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition, maintenance magnesium requirement</b>: <b>Note:</b> Magnesium sulfate is the preferred salt for parenteral nutrition mixtures; however, magnesium chloride may be appropriate in certain situations (eg, shortages) (ASPEN 2023; ESPGHAN/ESPEN/ESPR/CSPEN [Mihatsch 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children weighing ≤50 kg: Dose expressed as <b>elemental magnesium</b>: IV: 0.3 to 0.5 <b>mEq</b>/kg/day as an additive to parenteral nutrition (ASPEN 2020; ASPEN [Corkins 2015]; ASPEN [Mirtallo 2004]).</p>
<p style="text-indent:-2em;margin-left:4em;">Children weighing &gt;50 kg and Adolescents: Dose expressed as <b>elemental magnesium</b>: IV: 10 to 30 <b>mEq</b>/day as an additive to parenteral nutrition (ASPEN 2020; ASPEN [Corkins 2015]; ASPEN [Mirtallo 2004]).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51129133"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">According to the manufacturer's labeling, use is contraindicated in patients with renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51129134"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F190772"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Gastrointestinal: Diarrhea (excessive oral doses)</p></div>
<div class="block coi drugH1Div" id="F3011370"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">IV: Renal impairment; myocardial disease; coma.</p></div>
<div class="block war drugH1Div" id="F3011371"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Oral: Use with caution in patients with renal impairment; accumulation of magnesium may lead to magnesium intoxication.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Obstetrics: Vigilant monitoring and safe administration techniques (ISMP Medication Safety Alert 2005) recommended to avoid potential for errors resulting in toxicity. Monitor patient and fetal status, and serum magnesium levels closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte abnormalities: Concurrent hypokalemia or hypocalcemia can accompany a magnesium deficit. Hypomagnesemia is associated with hypokalemia and requires correction in order to normalize potassium.</p>
<p style="text-indent:-2em;margin-left:4em;">• Parenteral administration: Monitor serum magnesium level, respiratory rate, blood pressure, deep tendon reflex, and renal function when administered parenterally, particularly with repeated dosing; magnesium toxicity can lead to fatal cardiovascular arrest and/or respiratory paralysis.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878532"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Multiple salt forms of magnesium exist; pay close attention to the salt form when ordering and administering magnesium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or underdosing.</p></div>
<div class="block dosfc drugH1Div" id="F21963499"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:4em;">1 g magnesium chloride = elemental magnesium 119.7 mg = magnesium 9.85 mEq = magnesium 4.93 mmol</p>
<p style="text-indent:-2em;margin-left:4em;">Elemental magnesium 64 mg = magnesium 5.27 mEq = magnesium 2.63 mmol</p></div>
<div class="block foc drugH1Div" id="F190777"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hexahydrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg/mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nu-Mag: Elemental magnesium 71.5 mg (plus calcium 119 mg) [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Slow Magnesium/Calcium: 535 mg (elemental magnesium 64 mg, plus calcium 106 mg)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Slow-Mag: Elemental magnesium 71.5 mg (plus calcium 119 mg) [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SlowMag Mg Muscle/Heart: Elemental magnesium 71.5 mg (plus calcium 119 mg) [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p></div>
<div class="block geq drugH1Div" id="F190767"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F190781"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Magnesium Chloride Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/mL (per mL): $0.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Slow-Mag Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">71.5-119 mg (per each): $0.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (SlowMag Mg Muscle/Heart Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">71.5-119 mg (per each): $0.12</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57967659"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Hemodialysis: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5.15 g (5.15 g)</p></div>
<div class="block adm drugH1Div" id="F54279486"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Intermittent IV infusion: After dilution (concentration: 16 mg/mL magnesium chloride), infuse slowly at a rate not to exceed 48 mg/minute of magnesium chloride.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Do not chew or crush delayed-release formulations. Administer (preferably with food) at least 2 hours apart from other medications.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, delayed release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate.</p>
<p style="text-indent:-2em;margin-left:6em;">If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, clinicians should be aware that bariatric vitamin supplementation is recommended lifelong and may include magnesium. Consider integrating part or all of magnesium supplementation requirements into the postsurgery bariatric vitamin regimen.</p></div>
<div class="block admp drugH1Div" id="F52613207"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Tablet: Administration with food is preferred; do not chew or crush sustained-release formulations.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Intermittent IV infusion: After dilution (concentration: 16 mg/mL magnesium chloride), infuse slowly at a rate not to exceed 48 mg/minute of magnesium chloride.</p></div>
<div class="block use drugH1Div" id="F190779"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">Dietary supplement (oral): Dietary magnesium supplement.</p>
<p style="text-indent:-2em;margin-left:2em;">Hypomagnesemia (IV): As an electrolyte replenisher in patients with magnesium deficiencies.</p></div>
<div class="block cyt drugH1Div" id="F13299630"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F3011375"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfacalcidol: May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving alfacalcidol.  If magnesium-containing products must be used with alfacalcidol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: Magnesium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Magnesium Salts.  Management: Separate administration of alpha-lipoic acid from that of any magnesium-containing compounds by several hours. If alpha-lipoic acid is given 30 minutes before breakfast, then administer oral magnesium-containing products at lunch or dinner.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir.  Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir.  Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Magnesium Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral magnesium salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxercalciferol: May enhance the hypermagnesemic effect of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving doxercalciferol. If magnesium-containing products must be used with doxercalciferol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir.  Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gabapentin: Magnesium Salts may enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural magnesium sulfate may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after use of a magnesium-containing antacid. Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural magnesium sulfate is used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Magnesium Salts may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Magnesium Salts may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): Magnesium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, magnesium salts may decrease fluoride absorption.  Management: To avoid this potential interaction separate the administration of magnesium salts from administration of a fluoride-containing product by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE.  Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Magnesium Salts may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar/enox-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe/enox-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: Magnesium Salts may decrease the serum concentration of Raltegravir.  Management: Avoid the use of oral / enteral magnesium salts with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat.  Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Magnesium Salts may decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent.  Management: Avoid coadministration of oral magnesium salts and oral tetracyclines. If coadministration cannot be avoided, administer oral magnesium at least 2 hours before, or 4 hours after, oral tetracyclines. Monitor for decreased tetracycline therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine.  Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F3011366"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. Magnesium crosses the placenta; serum levels in the fetus correlate with those in the mother (Idama 1998; Osada 2002).</p></div>
<div class="block brc drugH1Div" id="F3011369"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Magnesium is found in breast milk; concentrations remain constant during the first year of lactation and are not influenced by dietary intake under normal conditions. Magnesium requirements are the same in lactating and non-lactating females (IOM 1997).</p></div>
<div class="block dic drugH1Div" id="F3011754"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Whole grains, legumes, and dark-green leafy vegetables are dietary sources of magnesium.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary reference intake (elemental magnesium) (IOM 1997): </b></p>
<p style="text-indent:-2em;margin-left:4em;">1 to 6 months: Adequate intake: 30 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">7 to 12 months: Adequate intake: 75 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 3 years: Recommended dietary allowance (RDA): 80 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">4 to 8 years: RDA: 130 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">9 to 13 years: RDA: 240 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">14 to 18 years: RDA:</p>
<p style="text-indent:-2em;margin-left:6em;">Females: 360 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Pregnancy: 400 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Lactation: 360 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Males: 410 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">19 to 30 years: RDA:</p>
<p style="text-indent:-2em;margin-left:6em;">Females: 310 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Pregnancy: 350 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Lactation: 310 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Males: 400 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">≥31 years: RDA:</p>
<p style="text-indent:-2em;margin-left:6em;">Females: 320 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Pregnancy: 360 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Lactation: 320 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Males: 420 mg/day.</p></div>
<div class="block mop drugH1Div" id="F3011755"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Rapid administration: ECG monitoring, vital signs, deep tendon reflexes; magnesium, calcium, and potassium levels; renal function during administration</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Renal function; magnesium levels; bowel movements</p></div>
<div class="block rer drugH1Div" id="F190778"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Adults: Serum magnesium: 1.5 to 2.5 mg/dL; slightly different ranges are reported by different laboratories.</p></div>
<div class="block pha drugH1Div" id="F3011747"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;text-align:justify;display:inline">Magnesium is important as a cofactor in many enzymatic reactions in the body involving protein synthesis and carbohydrate metabolism (at least 300 enzymatic reactions require magnesium). Actions on lipoprotein lipase have been found to be important in reducing serum cholesterol and on sodium/potassium ATPase in promoting polarization (eg, neuromuscular functioning).</p></div>
<div class="block phk drugH1Div" id="F3011749"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: Inversely proportional to amount ingested; 40% to 60% under controlled dietary conditions; 15% to 36% at higher doses</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Bone (50% to 60%); extracellular fluid (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 30%, to albumin</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (as magnesium)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F4088912"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Magnesium opti tabs</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Altavitam cloreto de magnesio | Cloreto de magnesio | Cloreto de magnesio p.a. | Cloreto de magnesio pa | Geromag p.a. | Magnesio | Panvel vita Cloreto de magnesio PA | Saudaliv cloreto de magnesio pa</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Magnesii chloridum</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Magnogene</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Magnesio cloruro</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Mag</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Magnogene</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Magnesium opti tabs</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Slow Mag</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Slow Mag</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Magnogene</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Balsol | Mag | Mag sr | Magni | Magni slow | Revite slow release magnesium | Slow Mag</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-chloride-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASPEN.2">
<a name="ASPEN.2"></a>American Society for Parenteral and Enteral Nutrition (ASPEN). Appropriate dosing for parenteral nutrition: ASPEN recommendations. http://www.nutritioncare.org/PNDosing. Updated November 17, 2020. Accessed January 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASPEN.1">
<a name="ASPEN.1"></a>American Society for Parenteral and Enteral Nutrition (ASPEN). Parenteral nutrition electrolyte and mineral product shortage considerations. https://www.nutritioncare.org/News/General_News/Parenteral_Nutrition_Electrolyte_and_Mineral_Product_Shortage_Considerations/. Accessed January 12, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-chloride-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Corkins.1">
<a name="Corkins.1"></a>Corkins MR, Balint J, Corkins KG, Bobo E, Plogsted S, Yaworski, JA, eds. <i>A.S.P.E.N. Pediatric Nutrition Support Handbook</i>. 2nd ed. Silver Spring, MD: American Society for Enteral and Parenteral Nutrition; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Greenbaum.1">
<a name="Greenbaum.1"></a>Greenbaum LA. Phosphorus. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020:chap. 68.5.</div>
</li>
<li>
<div class="reference">
                  Idama TO, Lindow SW. Magnesium Sulphate: A Review of Clinical Pharmacology Applied to Obstetrics. <i>Br J Obstet Gynaecol</i>. 1998;105(3):260-268.</div>
</li>
<li>
<div class="reference">
                  Institute for Safe Medication Practice (ISMP), “Preventing Magnesium Toxicity in Obstetrics,” <i>ISMP Acute Care Medication Safety Alert</i>, October 20, 2005. Available online at http://www.ismp.org/Newsletters/acutecare/articles/20051020.asp.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-chloride-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>Institute of Medicine (IOM). <i>Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride</i>. National Academy of Sciences; 1997.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lo.1">
<a name="Lo.1"></a>Lo SF. Reference intervals for laboratory tests and procedures. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap. 748.</div>
</li>
<li>
<div class="reference">
                  MagDelay (magnesium chloride) [prescribing information]. Livonia, MI: Major Pharmaceuticals; October 2018.</div>
</li>
<li>
<div class="reference">
                  Magnesium chloride injection [prescribing information]. Morgantown, WV: Mylan Institutional LLC; October 2021.</div>
</li>
<li>
<div class="reference">
                  Magnesium chloride tablet [prescribing information]. Dublin, OH: Cardinal Health; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30097365">
<a name="30097365"></a>Mihatsch W, Fewtrell M, Goulet O, et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Calcium, phosphorus and magnesium. <i>Clin Nutr</i>. 2018;37(6, pt B):2360-2365. doi:10.1016/j.clnu.2018.06.950<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-chloride-drug-information/abstract-text/30097365/pubmed" id="30097365" target="_blank">30097365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mirtallo.1">
<a name="Mirtallo.1"></a>Mirtallo J, Canada T, Johnson D, et al. Safe Practices for Parenteral Nutrition. <i>JPEN J Parenter Enteral Nutr</i>. 2004;28(6):39-70.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12366483">
<a name="12366483"></a>Osada H, Watanabe Y, Nishimura Y, at al. Profile of trace element concentrations in the feto-placental unit in relation to fetal growth. <i>Acta Obstet Gynecol Scand.</i> 2002;81(10):931-937.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-chloride-drug-information/abstract-text/12366483/pubmed" id="12366483" target="_blank">12366483</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Slow-Mag (magnesium chloride) [prescribing information]. Stamford, CT: Purdue Pharma; no date.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10122 Version 226.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
